AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Intro
This chapter explores the recent challenges faced by Novo Nordisk as its shares reach an 18-month low amid new drug price negotiations. It examines the broader implications for the obesity drug market and potential future strategies in response to evolving pricing pressures and competition.